Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Patients treated for DLBCL are at high risk of developing AICD. This adverse event is characterized by irreversible damage to the heart muscle with a loss of cardiomyocytes and subsequent decline in cardiac pumping capacity. Thereby patients treated for this malignancy are at double the risk of developing symptomatic heart failure / cardiomyopathy when compared to the general population. This corresponds to a cumulative incidence of 5-10% within 5-years after receiving R-CHOP. In the elderly, an incidence of 26% has been reported after 8-years of follow-up. Among patients who die in complete remission, heart failure has been described to be one of the most important causes of death. ANTICIPATE aims to evaluate if dexrazoxane can prevent AICD in DLBCL patients and identify those at highest risk of AICD. Of all patients treated with anthracyclines in a first-line setting, DLBCL patients were chosen for this trial for two primary reasons. Firstly, these patients have a favourable oncological prognosis with a 5-year relative survival in the Netherlands of 64-78% in those aged 18-74 years increasing the importance of preventing long-term toxicity. Secondly, the cumulative anthracycline dose used for the treatment of DLBCL is higher than the dose used in breast cancer. The cumulative anthracycline dose is the most important risk factor for AICD known.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Nowo rozpoznany chłoniak typu B-komórkowy potwierdzony badaniem laboratoryjnym
- •Wiek 18 lat lub więcej
- •Zaplanowana chemioterapia R-CHOP21 (6 cykli) lub podobne schematy leczenia
- •Ogólny stan zdrowia pacjenta pozwalający na leczenie chemioterapią
- •Ujemny test ciąży (dla kobiet w wieku rozrodczym)
- •Zgoda na zastosowanie antykoncepcji przez okres leczenia i 12 miesięcy po jego zakończeniu
- •Chłoniak w stopniu zaawansowania II-IV lub stopień I z guzem o wielkości 10 cm lub większym
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 23, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (25)
NL-Den Bosch-JBZ
's-Hertogenbosch, Netherlands
NL-Almelo-ZGTALMELO
Almelo, Netherlands
NL-Amstelveen-AMSTELLAND
Amstelveen, Netherlands
NL-Apeldoorn-GELREAPELDOORN
Apeldoorn, Netherlands
NL-Arnhem-RIJNSTATE
Arnhem, Netherlands
NL-Breda-AMPHIA
Breda, Netherlands
NL-Delft-RDGG
Delft, Netherlands
NL-Dordrecht-ASZ
Dordrecht, Netherlands
NL-Eindhoven-CATHARINA
Eindhoven, Netherlands
NL-Eindhoven-MAXIMAMC
Eindhoven, Netherlands
NL-Goes-ADRZ
Goes, Netherlands
NL-Groningen-MARTINI
Groningen, Netherlands
NL-Harderwijk-STJANSDALHARDERWIJK
Harderwijk, Netherlands
NL-Hilversum-TERGOOI
Hilversum, Netherlands
NL-Hoofddorp-SPAARNEGASTHUIS
Hoofddorp, Netherlands
NL-Nieuwegein-ANTONIUS
Nieuwegein, Netherlands
NL-Nijmegen-CWZ
Nijmegen, Netherlands
NL-Rotterdam-IKAZIA
Rotterdam, Netherlands
NL-Schiedam-FRANCISCUSVLIETLAND
Schiedam, Netherlands
NL-Sittard-ZUYDERLAND MC
Sittard, Netherlands
NL-Sneek-ANTONIUSSNEEK
Sneek, Netherlands
NL-Den Haag-HAGA
The Hague, Netherlands
NL-Utrecht-UMCUTRECHT
Utrecht, Netherlands
NL-Venlo-VIECURI
Venlo, Netherlands
NL-Zwolle-ISALA
Zwolle, Netherlands
Trial contact
A. van Rhenen, MD
M.P.M. Linschoten, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/24/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.